Stay updated with breaking news from Nasdaq Olma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have earned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have updated their coverage on the stock […]
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4...
ClariVest Asset Management LLC raised its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 23.9% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 65,900 shares of the company’s stock after buying an additional 12,700 shares during the period. ClariVest Asset Management LLC […]
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned an average recommendation of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last […]
Analysts at Citigroup started coverage on shares of Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) in a report released on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $20.00 price target on the stock. Citigroup’s price target points to a potential upside of 72.12% from the company’s current price. Separately, HC Wainwright […]